Agios Pharmaceuticals | AGIO - Прибыль до налогообложения





Прибыль до налогообложения Изменить Дата
AbbVie USD 5.57B 2.9B 2026-03
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Astellas Pharma JPY 48.02B 85.93B 2026-03
AstraZeneca USD 3.91B 1.28B 2026-03
Bayer EUR -3.37B 2.21B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Exelixis USD 267.69M 15M 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Merck USD 3.42B 3.32B 2025-12
Moderna USD -799M 612M 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Novartis USD 3.84B 802M 2026-03
Novartis USD 5.17B 637M 2025-09
Pfizer USD 5.18B 6.82B 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03